GRI Bio reports positive topline data from Phase 2a IPF study.

GRI Bio announced positive topline data from its Phase 2a study in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, with GRI-0621 being well-tolerated and no severe or serious adverse events. The study also met its secondary endpoints, demonstrating improvement in biomarkers of collagen turnover, suggesting a resolution of fibrosis and repair of the alveolar basement membrane. GRI-0621 showed increases in forced vital capacity (FVC) at 6 and 12 weeks of treatment.